Biomarkers for monitoring remodeling in a patient after a myocardial infarction
Posted in the Cardiology Forum
#1 Sep 2, 2011
A recent US patent application describes the use of biomarkers for monitoring success of remodeling in a patient after a myocardial infarction, wherein the remodeling is supported by treatment or a combination of treatments. A difference of 40% in inflammatory marker, osteopontin, indicates that administration of the drug can be lowered. A difference of 40% in inflammatory markers, osteopontin and GDF-15, indicates that administration of the drug can be lowered. A decrease to a difference of 33 pg/ml CRP indicates that administration of a drug can be lowered. News link: http://www.sciclips.com/sciclips/biomarker-ne...
Add your comments below
|Cardiologists, Veterinarian Work Together to Fi... (May '15)||Jun '16||Big Al||6|
|contribution of the left auricle and of the ven...||Jun '16||garry||2|
|Interpreting results of nuclear stress test (Jan '11)||Jun '16||Sue||13|
|Mr Heart||May '16||Echo||2|
|Southcoast Health touts heart implant procedure...||May '16||Patty||1|
|Are you an apple or a pear? Your shape may dete...||Apr '16||night rider||1|
|Sinus Tachycardia (Dec '15)||Apr '16||MartyWhite||2|
Find what you want!
Search Cardiology Forum Now
Copyright © 2016 Topix LLC